Literature DB >> 12634722

The whys and hows of hematopoietic progenitor and stem cell mobilization.

A Kessinger1, J G Sharp.   

Abstract

Intentional mobilization of hematopoietic/stem cells into the circulation has improved the efficiency of their collection. Transplantation of mobilized blood stem cells to patients with marrow aplasia results in a faster pace of hematopoietic recovery than transplantation of marrow-derived stem cells. Autologous and allogeneic hematopoietic stem cell transplantation are increasingly performed with blood-derived cells. Donors of both autologous and allogeneic blood stem cells do not always respond well to therapies designed to produce mobilization. Autologous donors may respond poorly as a result of myelotoxic damage inflicted by prior antitumor therapy, but this explanation is not valid for allogeneic donors. The mechanism(s) involved in the process of mobilization are incompletely understood. Until these mechanisms are elucidated, methods to improve mobilization vigor on a rational basis will not be obvious. In the meanwhile, clinical observations may provide some hints regarding the whys and hows of mobilization and permit incremental improvements in this process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634722     DOI: 10.1038/sj.bmt.1703837

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  On how Rac controls hematopoietic stem cell activity.

Authors:  J A Cancelas
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  Rho GTPases control specific cytoskeleton-dependent functions of hematopoietic stem cells.

Authors:  Ramesh C Nayak; Kyung-Hee Chang; Nataraja-Sarma Vaitinadin; Jose A Cancelas
Journal:  Immunol Rev       Date:  2013-11       Impact factor: 12.988

3.  A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Authors:  Hillard M Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M Hayes-Lattin; Asli Selmin Ataergin; Jacob D Bitran; Brian J Bolwell; César O Freytes; Robert Peter Gale; Steven C Goldstein; Gregory A Hale; David J Inwards; Thomas R Klumpp; David I Marks; Richard T Maziarz; Philip L McCarthy; Santiago Pavlovsky; J Douglas Rizzo; Thomas C Shea; Harry C Schouten; Shimon Slavin; Jane N Winter; Koen van Besien; Julie M Vose; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-04       Impact factor: 5.742

4.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

5.  Quantification of peripheral blood CD34+ cells prior to stem cell harvesting by leukapheresis: a single center experience.

Authors:  Natália Emerim Lemos; Mariela Granero Farias; Francyne Kubaski; Luciana Scotti; Tor Gunnar Hugo Onsten; Letícia de Almeida Brondani; Sandrine Comparsi Wagner; Leo Sekine
Journal:  Hematol Transfus Cell Ther       Date:  2018-03-15

6.  Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.

Authors:  Roberto Ria; Antonia Reale; Assunta Melaccio; Vito Racanelli; Franco Dammacco; Angelo Vacca
Journal:  Clin Exp Med       Date:  2014-04-11       Impact factor: 3.984

Review 7.  Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Louis M Pelus; Sherif S Farag
Journal:  Stem Cells Cloning       Date:  2011-02-27

Review 8.  Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

Authors:  Whitney D Wallis; Muzaffar H Qazilbash
Journal:  World J Transplant       Date:  2017-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.